Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2879015,bioavailability,"The mean bioavailability for amsacrine was 50% +/- 17 (s.d.) in non-fasting animals, and was significantly increased in fasting animals (mean, 90% +/- 10).","The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879015/),%,50,623,DB00276,Amsacrine
,2879015,bioavailability,"The mean bioavailability for amsacrine was 50% +/- 17 (s.d.) in non-fasting animals, and was significantly increased in fasting animals (mean, 90% +/- 10).","The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879015/),%,90,624,DB00276,Amsacrine
,2879015,bioavailability,"The bioavailability for CI-921 (mean, 26% +/- 11) in the non-fasting animal was significantly less than that found for amsacrine, but this difference disappeared in the fasting animal when the bioavailability of CI-921 was significantly increased to 69% +/- 23.","The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879015/),%,26,625,DB00276,Amsacrine
,2879015,bioavailability,"The bioavailability for CI-921 (mean, 26% +/- 11) in the non-fasting animal was significantly less than that found for amsacrine, but this difference disappeared in the fasting animal when the bioavailability of CI-921 was significantly increased to 69% +/- 23.","The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879015/),%,69,626,DB00276,Amsacrine
,9835899,Css plasma concentrations,"The Css plasma concentrations of ara-C and ara-U averaged 10.33 +/- 0.81 microM and 139.14 +/- 17.8 microM, respectively.",Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9835899/),μM,10.33,12079,DB00276,Amsacrine
,9835899,Css plasma concentrations,"The Css plasma concentrations of ara-C and ara-U averaged 10.33 +/- 0.81 microM and 139.14 +/- 17.8 microM, respectively.",Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9835899/),μM,139.14,12080,DB00276,Amsacrine
,3754493,p,This analogue is more lipophilic (0.5 log p units) and is also a considerable weaker base (pKa 6.40) than amsacrine (pKa 7.43).,"Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754493/),,6.40,14637,DB00276,Amsacrine
,3754493,unbound fraction,"However, the unbound fraction was significantly less for CI-921 (0.33% +/- 0.04) than for amsacrine (2.78% +/- 0.53).","Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754493/),%,0.33,14638,DB00276,Amsacrine
,3754493,unbound fraction,"However, the unbound fraction was significantly less for CI-921 (0.33% +/- 0.04) than for amsacrine (2.78% +/- 0.53).","Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754493/),%,2.78,14639,DB00276,Amsacrine
,3754493,apparent volume of distribution,"There was no significant difference between distribution and elimination half-life and mean residence time, but the apparent volume of distribution (means, 121 vs 45 l/kg) and clearance (means, 46.6 vs 16.3 l h-1 kg-1) of unbound CI-921 were threefold greater than the corresponding parameters for unbound amsacrine.","Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754493/),[l] / [kg],121,14640,DB00276,Amsacrine
,3754493,apparent volume of distribution,"There was no significant difference between distribution and elimination half-life and mean residence time, but the apparent volume of distribution (means, 121 vs 45 l/kg) and clearance (means, 46.6 vs 16.3 l h-1 kg-1) of unbound CI-921 were threefold greater than the corresponding parameters for unbound amsacrine.","Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754493/),[l] / [kg],45,14641,DB00276,Amsacrine
,3754493,clearance,"There was no significant difference between distribution and elimination half-life and mean residence time, but the apparent volume of distribution (means, 121 vs 45 l/kg) and clearance (means, 46.6 vs 16.3 l h-1 kg-1) of unbound CI-921 were threefold greater than the corresponding parameters for unbound amsacrine.","Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754493/),[l] / [h·kg],46.6,14642,DB00276,Amsacrine
,3754493,clearance,"There was no significant difference between distribution and elimination half-life and mean residence time, but the apparent volume of distribution (means, 121 vs 45 l/kg) and clearance (means, 46.6 vs 16.3 l h-1 kg-1) of unbound CI-921 were threefold greater than the corresponding parameters for unbound amsacrine.","Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3754493/),[l] / [h·kg],16.3,14643,DB00276,Amsacrine
,6687834,terminal plasma half-life,The mean terminal plasma half-life for total 14C ranged from 34 hr in patients with normal organ function to 46 hr in patients with severe liver disease.,"Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687834/),h,34,20467,DB00276,Amsacrine
,6687834,terminal plasma half-life,The mean terminal plasma half-life for total 14C ranged from 34 hr in patients with normal organ function to 46 hr in patients with severe liver disease.,"Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687834/),h,46,20468,DB00276,Amsacrine
,6687834,plasma half-life,"For unchanged amsacrine, the mean values of plasma half-life were 7.4 and 17.2 hr for patients with normal and abnormal liver function, respectively.","Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687834/),h,7.4,20469,DB00276,Amsacrine
,6687834,plasma half-life,"For unchanged amsacrine, the mean values of plasma half-life were 7.4 and 17.2 hr for patients with normal and abnormal liver function, respectively.","Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687834/),h,17.2,20470,DB00276,Amsacrine
,6687834,cumulative urinary excretion,"The mean 72-hr cumulative urinary excretion of total 14C varied from 35% in normal patients to 49% in patients with severe liver disease, while patients with renal disease excreted only 2 to 16%.","Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687834/),%,35,20471,DB00276,Amsacrine
,6687834,cumulative urinary excretion,"The mean 72-hr cumulative urinary excretion of total 14C varied from 35% in normal patients to 49% in patients with severe liver disease, while patients with renal disease excreted only 2 to 16%.","Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687834/),%,49,20472,DB00276,Amsacrine
,6687834,cumulative urinary excretion,"The mean 72-hr cumulative urinary excretion of total 14C varied from 35% in normal patients to 49% in patients with severe liver disease, while patients with renal disease excreted only 2 to 16%.","Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687834/),%,2,20473,DB00276,Amsacrine
,6687834,urinary excretion,"In comparison, the urinary excretion of unchanged amsacrine was 12, 20 and 2% of the administered dose, respectively, in these same patients.","Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687834/),%,12,20474,DB00276,Amsacrine
,6687834,urinary excretion,"In comparison, the urinary excretion of unchanged amsacrine was 12, 20 and 2% of the administered dose, respectively, in these same patients.","Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687834/),%,20,20475,DB00276,Amsacrine
,6687834,urinary excretion,"In comparison, the urinary excretion of unchanged amsacrine was 12, 20 and 2% of the administered dose, respectively, in these same patients.","Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6687834/),%,2,20476,DB00276,Amsacrine
,8070033,response rates,The response rates of patients with small-cell lung cancer receiving a 24-h infusion was only 10% as compared with 89% when the same dose was given over 5 days.,Schedule-dependent topoisomerase II-inhibiting drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070033/),%,10,23294,DB00276,Amsacrine
,8070033,response rates,The response rates of patients with small-cell lung cancer receiving a 24-h infusion was only 10% as compared with 89% when the same dose was given over 5 days.,Schedule-dependent topoisomerase II-inhibiting drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070033/),%,89,23295,DB00276,Amsacrine
,8472810,peak concentrations,Median plasma and nucleated blood cell peak concentrations were 1.25 and 6.36 micrograms/ml followed by biphasic elimination with a median T1/2 alpha alpha of 1.6 h and 0.3 h and a median T1/2 beta of 5.0 h and 5.0 h respectively.,"Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),[μg] / [ml],1.25,24567,DB00276,Amsacrine
,8472810,peak concentrations,Median plasma and nucleated blood cell peak concentrations were 1.25 and 6.36 micrograms/ml followed by biphasic elimination with a median T1/2 alpha alpha of 1.6 h and 0.3 h and a median T1/2 beta of 5.0 h and 5.0 h respectively.,"Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),[μg] / [ml],6.36,24568,DB00276,Amsacrine
,8472810,T1/2 alpha alpha,Median plasma and nucleated blood cell peak concentrations were 1.25 and 6.36 micrograms/ml followed by biphasic elimination with a median T1/2 alpha alpha of 1.6 h and 0.3 h and a median T1/2 beta of 5.0 h and 5.0 h respectively.,"Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),h,1.6,24569,DB00276,Amsacrine
,8472810,T1/2 alpha alpha,Median plasma and nucleated blood cell peak concentrations were 1.25 and 6.36 micrograms/ml followed by biphasic elimination with a median T1/2 alpha alpha of 1.6 h and 0.3 h and a median T1/2 beta of 5.0 h and 5.0 h respectively.,"Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),h,0.3,24570,DB00276,Amsacrine
,8472810,T1/2 beta,Median plasma and nucleated blood cell peak concentrations were 1.25 and 6.36 micrograms/ml followed by biphasic elimination with a median T1/2 alpha alpha of 1.6 h and 0.3 h and a median T1/2 beta of 5.0 h and 5.0 h respectively.,"Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),h,5.0,24571,DB00276,Amsacrine
,8472810,plasma,Median plasma and cellular area under the curve (AUC) for a 24-h period amounted 6.2 micrograms.h/ml and 49.8 micrograms.h/ml respectively.,"Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),[h·μg] / [ml],6.2,24572,DB00276,Amsacrine
,8472810,area under the curve (AUC),Median plasma and cellular area under the curve (AUC) for a 24-h period amounted 6.2 micrograms.h/ml and 49.8 micrograms.h/ml respectively.,"Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),[h·μg] / [ml],49.8,24573,DB00276,Amsacrine
,8472810,IC50,"Median IC50 for CFU-GM and CFU-L was 2.2, 1.8 and 1.6 micrograms/ml after incubation periods of resp. 0.08, 4 and 24 h.","Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),[μg] / [ml],2.2,24574,DB00276,Amsacrine
,8472810,IC50,"Median IC50 for CFU-GM and CFU-L was 2.2, 1.8 and 1.6 micrograms/ml after incubation periods of resp. 0.08, 4 and 24 h.","Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),[μg] / [ml],1.8,24575,DB00276,Amsacrine
,8472810,IC50,"Median IC50 for CFU-GM and CFU-L was 2.2, 1.8 and 1.6 micrograms/ml after incubation periods of resp. 0.08, 4 and 24 h.","Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),[μg] / [ml],1.6,24576,DB00276,Amsacrine
,8472810,concentration x time products to achieve 50% inhibition (IAUC50),"The corresponding m-AMSA concentration x time products to achieve 50% inhibition (IAUC50) were 0.18, 7.2 and 38.4 micrograms.h/ml, respectively.","Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),[h·μg] / [ml],0.18,24577,DB00276,Amsacrine
,8472810,concentration x time products to achieve 50% inhibition (IAUC50),"The corresponding m-AMSA concentration x time products to achieve 50% inhibition (IAUC50) were 0.18, 7.2 and 38.4 micrograms.h/ml, respectively.","Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),[h·μg] / [ml],7.2,24578,DB00276,Amsacrine
,8472810,concentration x time products to achieve 50% inhibition (IAUC50),"The corresponding m-AMSA concentration x time products to achieve 50% inhibition (IAUC50) were 0.18, 7.2 and 38.4 micrograms.h/ml, respectively.","Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472810/),[h·μg] / [ml],38.4,24579,DB00276,Amsacrine
,6549572,half-life,"Intraventricular administration of drug achieved high initial ventricular fluid concentrations, but the drug was rapidly cleared with a half-life of 115 min.",Intrathecally administered m-AMSA in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6549572/),min,115,26847,DB00276,Amsacrine
,11855748,Oral bioavailability,Oral bioavailability of 50 mg/m2 amsalog was 34%.,"A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855748/),%,34,49611,DB00276,Amsacrine
,11855748,MTD,The MTD was 1600 mg/m2 per day for 5 days.,"A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855748/),[mg] / [m2],1600,49612,DB00276,Amsacrine
,3672568,terminal elimination half-life,"The mean terminal elimination half-life of AMSA-NCL and AMSA-lactate was 7.1 and 6.3 h, respectively, and the mean volume of distribution was 105 and 99 L/m2, respectively.",Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3672568/),h,7.1,64445,DB00276,Amsacrine
,3672568,terminal elimination half-life,"The mean terminal elimination half-life of AMSA-NCL and AMSA-lactate was 7.1 and 6.3 h, respectively, and the mean volume of distribution was 105 and 99 L/m2, respectively.",Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3672568/),h,6.3,64446,DB00276,Amsacrine
,3672568,volume of distribution,"The mean terminal elimination half-life of AMSA-NCL and AMSA-lactate was 7.1 and 6.3 h, respectively, and the mean volume of distribution was 105 and 99 L/m2, respectively.",Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3672568/),[l] / [m2],105,64447,DB00276,Amsacrine
,3672568,volume of distribution,"The mean terminal elimination half-life of AMSA-NCL and AMSA-lactate was 7.1 and 6.3 h, respectively, and the mean volume of distribution was 105 and 99 L/m2, respectively.",Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3672568/),[l] / [m2],99,64448,DB00276,Amsacrine
,18848873,C(max),"In plasma, ASL nanosuspension exhibited a significantly (P<0.01) reduced C(max) (12.2+/-1.3microg ml(-1)vs 18.3+/-1.0microg ml(-1)) and AUC(0-infinity) (18.7+/-0.5microg ml(-1)h vs 46.4+/-2.6microg ml(-1)h), and a significantly (P<0.01) greater volume of distribution (15.5+/-0.6lkg(-1)vs 2.5+/-0.1lkg(-1)), clearance (1.6+/-0.04lh(-1)kg(-1)vs 0.6+/-0.04lh(-1)kg(-1)) and elimination half-life (6.1+/-0.1h vs 2.7+/-0.2h) compared to the ASL solution.",Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18848873/),[μg] / [ml],12.2,69529,DB00276,Amsacrine
,18848873,C(max),"In plasma, ASL nanosuspension exhibited a significantly (P<0.01) reduced C(max) (12.2+/-1.3microg ml(-1)vs 18.3+/-1.0microg ml(-1)) and AUC(0-infinity) (18.7+/-0.5microg ml(-1)h vs 46.4+/-2.6microg ml(-1)h), and a significantly (P<0.01) greater volume of distribution (15.5+/-0.6lkg(-1)vs 2.5+/-0.1lkg(-1)), clearance (1.6+/-0.04lh(-1)kg(-1)vs 0.6+/-0.04lh(-1)kg(-1)) and elimination half-life (6.1+/-0.1h vs 2.7+/-0.2h) compared to the ASL solution.",Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18848873/),[μg] / [ml],18.3,69530,DB00276,Amsacrine
,18848873,AUC(0-infinity),"In plasma, ASL nanosuspension exhibited a significantly (P<0.01) reduced C(max) (12.2+/-1.3microg ml(-1)vs 18.3+/-1.0microg ml(-1)) and AUC(0-infinity) (18.7+/-0.5microg ml(-1)h vs 46.4+/-2.6microg ml(-1)h), and a significantly (P<0.01) greater volume of distribution (15.5+/-0.6lkg(-1)vs 2.5+/-0.1lkg(-1)), clearance (1.6+/-0.04lh(-1)kg(-1)vs 0.6+/-0.04lh(-1)kg(-1)) and elimination half-life (6.1+/-0.1h vs 2.7+/-0.2h) compared to the ASL solution.",Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18848873/),[μg] / [ml],18.7,69531,DB00276,Amsacrine
,18848873,AUC(0-infinity),"In plasma, ASL nanosuspension exhibited a significantly (P<0.01) reduced C(max) (12.2+/-1.3microg ml(-1)vs 18.3+/-1.0microg ml(-1)) and AUC(0-infinity) (18.7+/-0.5microg ml(-1)h vs 46.4+/-2.6microg ml(-1)h), and a significantly (P<0.01) greater volume of distribution (15.5+/-0.6lkg(-1)vs 2.5+/-0.1lkg(-1)), clearance (1.6+/-0.04lh(-1)kg(-1)vs 0.6+/-0.04lh(-1)kg(-1)) and elimination half-life (6.1+/-0.1h vs 2.7+/-0.2h) compared to the ASL solution.",Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18848873/),[μg] / [ml],46.4,69532,DB00276,Amsacrine
,18848873,volume of distribution,"In plasma, ASL nanosuspension exhibited a significantly (P<0.01) reduced C(max) (12.2+/-1.3microg ml(-1)vs 18.3+/-1.0microg ml(-1)) and AUC(0-infinity) (18.7+/-0.5microg ml(-1)h vs 46.4+/-2.6microg ml(-1)h), and a significantly (P<0.01) greater volume of distribution (15.5+/-0.6lkg(-1)vs 2.5+/-0.1lkg(-1)), clearance (1.6+/-0.04lh(-1)kg(-1)vs 0.6+/-0.04lh(-1)kg(-1)) and elimination half-life (6.1+/-0.1h vs 2.7+/-0.2h) compared to the ASL solution.",Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18848873/),1/[lkg],15.5,69533,DB00276,Amsacrine
,18848873,volume of distribution,"In plasma, ASL nanosuspension exhibited a significantly (P<0.01) reduced C(max) (12.2+/-1.3microg ml(-1)vs 18.3+/-1.0microg ml(-1)) and AUC(0-infinity) (18.7+/-0.5microg ml(-1)h vs 46.4+/-2.6microg ml(-1)h), and a significantly (P<0.01) greater volume of distribution (15.5+/-0.6lkg(-1)vs 2.5+/-0.1lkg(-1)), clearance (1.6+/-0.04lh(-1)kg(-1)vs 0.6+/-0.04lh(-1)kg(-1)) and elimination half-life (6.1+/-0.1h vs 2.7+/-0.2h) compared to the ASL solution.",Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18848873/),1/[lkg],2.5,69534,DB00276,Amsacrine
,18848873,clearance,"In plasma, ASL nanosuspension exhibited a significantly (P<0.01) reduced C(max) (12.2+/-1.3microg ml(-1)vs 18.3+/-1.0microg ml(-1)) and AUC(0-infinity) (18.7+/-0.5microg ml(-1)h vs 46.4+/-2.6microg ml(-1)h), and a significantly (P<0.01) greater volume of distribution (15.5+/-0.6lkg(-1)vs 2.5+/-0.1lkg(-1)), clearance (1.6+/-0.04lh(-1)kg(-1)vs 0.6+/-0.04lh(-1)kg(-1)) and elimination half-life (6.1+/-0.1h vs 2.7+/-0.2h) compared to the ASL solution.",Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18848873/),1/[lh],1.6,69535,DB00276,Amsacrine
,18848873,clearance,"In plasma, ASL nanosuspension exhibited a significantly (P<0.01) reduced C(max) (12.2+/-1.3microg ml(-1)vs 18.3+/-1.0microg ml(-1)) and AUC(0-infinity) (18.7+/-0.5microg ml(-1)h vs 46.4+/-2.6microg ml(-1)h), and a significantly (P<0.01) greater volume of distribution (15.5+/-0.6lkg(-1)vs 2.5+/-0.1lkg(-1)), clearance (1.6+/-0.04lh(-1)kg(-1)vs 0.6+/-0.04lh(-1)kg(-1)) and elimination half-life (6.1+/-0.1h vs 2.7+/-0.2h) compared to the ASL solution.",Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18848873/),1/[lh],0.6,69536,DB00276,Amsacrine
,18848873,elimination half-life,"In plasma, ASL nanosuspension exhibited a significantly (P<0.01) reduced C(max) (12.2+/-1.3microg ml(-1)vs 18.3+/-1.0microg ml(-1)) and AUC(0-infinity) (18.7+/-0.5microg ml(-1)h vs 46.4+/-2.6microg ml(-1)h), and a significantly (P<0.01) greater volume of distribution (15.5+/-0.6lkg(-1)vs 2.5+/-0.1lkg(-1)), clearance (1.6+/-0.04lh(-1)kg(-1)vs 0.6+/-0.04lh(-1)kg(-1)) and elimination half-life (6.1+/-0.1h vs 2.7+/-0.2h) compared to the ASL solution.",Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18848873/),h,6.1,69537,DB00276,Amsacrine
,18848873,elimination half-life,"In plasma, ASL nanosuspension exhibited a significantly (P<0.01) reduced C(max) (12.2+/-1.3microg ml(-1)vs 18.3+/-1.0microg ml(-1)) and AUC(0-infinity) (18.7+/-0.5microg ml(-1)h vs 46.4+/-2.6microg ml(-1)h), and a significantly (P<0.01) greater volume of distribution (15.5+/-0.6lkg(-1)vs 2.5+/-0.1lkg(-1)), clearance (1.6+/-0.04lh(-1)kg(-1)vs 0.6+/-0.04lh(-1)kg(-1)) and elimination half-life (6.1+/-0.1h vs 2.7+/-0.2h) compared to the ASL solution.",Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18848873/),h,2.7,69538,DB00276,Amsacrine
,9853980,CR rate,The CR rate after two courses with this regimen was 77%.,High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853980/),%,77,71027,DB00276,Amsacrine
,3855288,t1/2 alpha,Postinfusion amsacrine elimination was best described by a biexponential expression with a mean t1/2 alpha of 0.8 h and a terminal t1/2 beta of 5.3 h.,Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855288/),h,0.8,80841,DB00276,Amsacrine
,3855288,terminal t1/2 beta,Postinfusion amsacrine elimination was best described by a biexponential expression with a mean t1/2 alpha of 0.8 h and a terminal t1/2 beta of 5.3 h.,Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855288/),h,5.3,80842,DB00276,Amsacrine
greater,3855288,Cl,"Two distinct groups were apparent after the first infusion, patients with a Cl greater than 294 and those with a Cl less than 208 ml . h-1 . kg-1.",Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855288/),,294,80843,DB00276,Amsacrine
less,3855288,Cl,"Two distinct groups were apparent after the first infusion, patients with a Cl greater than 294 and those with a Cl less than 208 ml . h-1 . kg-1.",Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855288/),[ml] / [h·kg],208,80844,DB00276,Amsacrine
,11345650,terminal half-life,"The terminal half-life was 2 h, consistent with previous studies.",A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345650/),h,2,89537,DB00276,Amsacrine
,15925259,flow rate,A C(18) 250 mm x 4mm column was used for the separation of analyte with a mobile phase consisting of 50% acetonitrile and 50% pH 3.0 of sodium 1-pentansulfonate solution at a flow rate of 1.0 mL/min.,"Highly sensitive analysis of the anti-tumor agent 1-[4-(furo[2,3-b]-quinolin-4-ylamino)phenyl]ethanone in rat plasma by high-performance liquid chromatography using electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15925259/),[ml] / [min],1.0,107268,DB00276,Amsacrine
,15925259,lower limit of detection (LOD),The lower limit of detection (LOD) was 0.5 ng/mL.,"Highly sensitive analysis of the anti-tumor agent 1-[4-(furo[2,3-b]-quinolin-4-ylamino)phenyl]ethanone in rat plasma by high-performance liquid chromatography using electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15925259/),[ng] / [ml],0.5,107269,DB00276,Amsacrine
,3180070,Peak plasma concentrations,Peak plasma concentrations ranged from 3.36 to 85.6 mumol/liter and were significantly correlated with dose.,"Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180070/),[μM] / [l],3.36 to 85.6,121344,DB00276,Amsacrine
,3180070,distribution half-life,"Mean (range) model-independent pharmacokinetic parameters were: distribution half-life, 0.46 h (0.24-1.08); elimination half-life, 2.63 h (1.08-4.98); mean residence time, 2.0 h (1.05-3.35); plasma clearance, 158 ml/h/kg (95-290); and steady-state volume of distribution, 319 ml/kg (219-614) with no significant difference between Day 1 and 3.","Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180070/),h,0.46,121345,DB00276,Amsacrine
,3180070,elimination half-life,"Mean (range) model-independent pharmacokinetic parameters were: distribution half-life, 0.46 h (0.24-1.08); elimination half-life, 2.63 h (1.08-4.98); mean residence time, 2.0 h (1.05-3.35); plasma clearance, 158 ml/h/kg (95-290); and steady-state volume of distribution, 319 ml/kg (219-614) with no significant difference between Day 1 and 3.","Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180070/),h,2.63,121346,DB00276,Amsacrine
,3180070,mean residence time,"Mean (range) model-independent pharmacokinetic parameters were: distribution half-life, 0.46 h (0.24-1.08); elimination half-life, 2.63 h (1.08-4.98); mean residence time, 2.0 h (1.05-3.35); plasma clearance, 158 ml/h/kg (95-290); and steady-state volume of distribution, 319 ml/kg (219-614) with no significant difference between Day 1 and 3.","Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180070/),h,2.0,121347,DB00276,Amsacrine
,3180070,plasma clearance,"Mean (range) model-independent pharmacokinetic parameters were: distribution half-life, 0.46 h (0.24-1.08); elimination half-life, 2.63 h (1.08-4.98); mean residence time, 2.0 h (1.05-3.35); plasma clearance, 158 ml/h/kg (95-290); and steady-state volume of distribution, 319 ml/kg (219-614) with no significant difference between Day 1 and 3.","Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180070/),[ml] / [h·kg],158,121348,DB00276,Amsacrine
,3180070,steady-state volume of distribution,"Mean (range) model-independent pharmacokinetic parameters were: distribution half-life, 0.46 h (0.24-1.08); elimination half-life, 2.63 h (1.08-4.98); mean residence time, 2.0 h (1.05-3.35); plasma clearance, 158 ml/h/kg (95-290); and steady-state volume of distribution, 319 ml/kg (219-614) with no significant difference between Day 1 and 3.","Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921). ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180070/),[ml] / [kg],319,121349,DB00276,Amsacrine
,3409457,Maximum plasma concentrations,Maximum plasma concentrations ranged from 3-86 mumol/l.,The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409457/),[μM] / [l],3-86,144090,DB00276,Amsacrine
,3409457,CL,"The means (range) of model-independent pharmacokinetic parameters were: CL, 158 (94-290) ml/h per kg; Vss, 319 (219-614) ml/kg; MRT, 2.1 (1.1-3.5) h; t1/2 alpha, 0.5 (0.2-1.1) h; and t1/2 beta, 2.6 (1.1-5.0) h.",The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409457/),[ml] / [h·kg],158,144091,DB00276,Amsacrine
,3409457,Vss,"The means (range) of model-independent pharmacokinetic parameters were: CL, 158 (94-290) ml/h per kg; Vss, 319 (219-614) ml/kg; MRT, 2.1 (1.1-3.5) h; t1/2 alpha, 0.5 (0.2-1.1) h; and t1/2 beta, 2.6 (1.1-5.0) h.",The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409457/),[ml] / [kg],319,144092,DB00276,Amsacrine
,3409457,MRT,"The means (range) of model-independent pharmacokinetic parameters were: CL, 158 (94-290) ml/h per kg; Vss, 319 (219-614) ml/kg; MRT, 2.1 (1.1-3.5) h; t1/2 alpha, 0.5 (0.2-1.1) h; and t1/2 beta, 2.6 (1.1-5.0) h.",The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409457/),h,2.1,144093,DB00276,Amsacrine
,3409457,t1/2 alpha,"The means (range) of model-independent pharmacokinetic parameters were: CL, 158 (94-290) ml/h per kg; Vss, 319 (219-614) ml/kg; MRT, 2.1 (1.1-3.5) h; t1/2 alpha, 0.5 (0.2-1.1) h; and t1/2 beta, 2.6 (1.1-5.0) h.",The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409457/),h,0.5,144094,DB00276,Amsacrine
,3409457,t1/2 beta,"The means (range) of model-independent pharmacokinetic parameters were: CL, 158 (94-290) ml/h per kg; Vss, 319 (219-614) ml/kg; MRT, 2.1 (1.1-3.5) h; t1/2 alpha, 0.5 (0.2-1.1) h; and t1/2 beta, 2.6 (1.1-5.0) h.",The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409457/),h,2.6,144095,DB00276,Amsacrine
,23055719,half-life alpha,"After intravenous bolus of the PK-L4-loaded SLNs with PEG, there was a marked significant difference in half-life alpha (0.136 ± 0.046 hours) when compared with the PK-L4 solution (0.078 ± 0.023 hours); also the area under the curve from zero to infinity did not change in plasma when compared to the PK-L4 solution.",Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23055719/),h,0.136,157084,DB00276,Amsacrine
,23055719,half-life alpha,"After intravenous bolus of the PK-L4-loaded SLNs with PEG, there was a marked significant difference in half-life alpha (0.136 ± 0.046 hours) when compared with the PK-L4 solution (0.078 ± 0.023 hours); also the area under the curve from zero to infinity did not change in plasma when compared to the PK-L4 solution.",Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23055719/),h,0.078,157085,DB00276,Amsacrine
,3839584,t 1/2 alpha,All elimination curves were best fitted by a bi-exponential expression with a mean t 1/2 alpha of 0.56 h and t 1/2 beta of 2.47 h.,Elimination kinetics of amsacrine in the rabbit: evidence of nonlinearity. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3839584/),h,0.56,163279,DB00276,Amsacrine
,3839584,t 1/2 beta,All elimination curves were best fitted by a bi-exponential expression with a mean t 1/2 alpha of 0.56 h and t 1/2 beta of 2.47 h.,Elimination kinetics of amsacrine in the rabbit: evidence of nonlinearity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3839584/),h,2.47,163280,DB00276,Amsacrine
,2297692,Km,"Over this dose range, nonlinear kinetics were observed in plasma for unchanged CI-921 and amsacrine, and a reasonable fit was obtained with Michaelis-Menten kinetics to a one-compartment model for CI-921 (Km 3.7 mumol/liter; Vmax 18 mumol/h/kg; V ss 3.3 liter/kg) and a two-compartment model for amsacrine (Km 3.6 mumol/liter; Vmax 76 mumol/h/kg; Vss 4.8 liter/kg).","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),[μM] / [l],3.7,166907,DB00276,Amsacrine
,2297692,Vmax,"Over this dose range, nonlinear kinetics were observed in plasma for unchanged CI-921 and amsacrine, and a reasonable fit was obtained with Michaelis-Menten kinetics to a one-compartment model for CI-921 (Km 3.7 mumol/liter; Vmax 18 mumol/h/kg; V ss 3.3 liter/kg) and a two-compartment model for amsacrine (Km 3.6 mumol/liter; Vmax 76 mumol/h/kg; Vss 4.8 liter/kg).","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),[μM] / [h·kg],18,166908,DB00276,Amsacrine
,2297692,V ss,"Over this dose range, nonlinear kinetics were observed in plasma for unchanged CI-921 and amsacrine, and a reasonable fit was obtained with Michaelis-Menten kinetics to a one-compartment model for CI-921 (Km 3.7 mumol/liter; Vmax 18 mumol/h/kg; V ss 3.3 liter/kg) and a two-compartment model for amsacrine (Km 3.6 mumol/liter; Vmax 76 mumol/h/kg; Vss 4.8 liter/kg).","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),[l] / [kg],3.3,166909,DB00276,Amsacrine
,2297692,Km,"Over this dose range, nonlinear kinetics were observed in plasma for unchanged CI-921 and amsacrine, and a reasonable fit was obtained with Michaelis-Menten kinetics to a one-compartment model for CI-921 (Km 3.7 mumol/liter; Vmax 18 mumol/h/kg; V ss 3.3 liter/kg) and a two-compartment model for amsacrine (Km 3.6 mumol/liter; Vmax 76 mumol/h/kg; Vss 4.8 liter/kg).","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),[μM] / [l],3.6,166910,DB00276,Amsacrine
,2297692,Vmax,"Over this dose range, nonlinear kinetics were observed in plasma for unchanged CI-921 and amsacrine, and a reasonable fit was obtained with Michaelis-Menten kinetics to a one-compartment model for CI-921 (Km 3.7 mumol/liter; Vmax 18 mumol/h/kg; V ss 3.3 liter/kg) and a two-compartment model for amsacrine (Km 3.6 mumol/liter; Vmax 76 mumol/h/kg; Vss 4.8 liter/kg).","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),[μM] / [h·kg],76,166911,DB00276,Amsacrine
,2297692,Vss,"Over this dose range, nonlinear kinetics were observed in plasma for unchanged CI-921 and amsacrine, and a reasonable fit was obtained with Michaelis-Menten kinetics to a one-compartment model for CI-921 (Km 3.7 mumol/liter; Vmax 18 mumol/h/kg; V ss 3.3 liter/kg) and a two-compartment model for amsacrine (Km 3.6 mumol/liter; Vmax 76 mumol/h/kg; Vss 4.8 liter/kg).","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),[l] / [kg],4.8,166912,DB00276,Amsacrine
,2297692,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) for plasma following a dose of 57.7 mumol/kg was 31 mumol.h/liter for CI-921 and 6.3 mumol.h/liter for amsacrine.,"Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),[h·μM] / [l],31,166913,DB00276,Amsacrine
,2297692,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) for plasma following a dose of 57.7 mumol/kg was 31 mumol.h/liter for CI-921 and 6.3 mumol.h/liter for amsacrine.,"Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),[h·μM] / [l],6.3,166914,DB00276,Amsacrine
,2297692,plasma protein binding,"However, equilibrium dialysis measurements indicated high plasma protein binding with free drug fractions for CI-921 and amsacrine of 0.63 and 6.7%, respectively.","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),%,0.63,166915,DB00276,Amsacrine
,2297692,plasma protein binding,"However, equilibrium dialysis measurements indicated high plasma protein binding with free drug fractions for CI-921 and amsacrine of 0.63 and 6.7%, respectively.","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),%,6.7,166916,DB00276,Amsacrine
,2297692,Tumor half-lives,"Tumor half-lives of unchanged CI-921 and amsacrine were 3.9 and 2.7 h, respectively, considerably longer than those for plasma (1.2 and 0.30 h respectively) or liver (1.2 and 0.28 h, respectively).","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),h,3.9,166917,DB00276,Amsacrine
,2297692,Tumor half-lives,"Tumor half-lives of unchanged CI-921 and amsacrine were 3.9 and 2.7 h, respectively, considerably longer than those for plasma (1.2 and 0.30 h respectively) or liver (1.2 and 0.28 h, respectively).","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),h,2.7,166918,DB00276,Amsacrine
,2297692,Tumor half-lives,"Tumor half-lives of unchanged CI-921 and amsacrine were 3.9 and 2.7 h, respectively, considerably longer than those for plasma (1.2 and 0.30 h respectively) or liver (1.2 and 0.28 h, respectively).","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),h,1.2,166919,DB00276,Amsacrine
,2297692,Tumor half-lives,"Tumor half-lives of unchanged CI-921 and amsacrine were 3.9 and 2.7 h, respectively, considerably longer than those for plasma (1.2 and 0.30 h respectively) or liver (1.2 and 0.28 h, respectively).","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),h,0.30,166920,DB00276,Amsacrine
,2297692,Tumor half-lives,"Tumor half-lives of unchanged CI-921 and amsacrine were 3.9 and 2.7 h, respectively, considerably longer than those for plasma (1.2 and 0.30 h respectively) or liver (1.2 and 0.28 h, respectively).","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),h,0.28,166921,DB00276,Amsacrine
,2297692,AUC,"Tumor AUC values for CI-921 and amsacrine were 68 and 37 mumol.h/liter, respectively, as compared to the calculated AUC values for free drug in plasma of 0.19 and 0.42 mumol.h/liter, respectively.","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),[h·μM] / [l],68,166922,DB00276,Amsacrine
,2297692,AUC,"Tumor AUC values for CI-921 and amsacrine were 68 and 37 mumol.h/liter, respectively, as compared to the calculated AUC values for free drug in plasma of 0.19 and 0.42 mumol.h/liter, respectively.","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),[h·μM] / [l],37,166923,DB00276,Amsacrine
,2297692,AUC,"Tumor AUC values for CI-921 and amsacrine were 68 and 37 mumol.h/liter, respectively, as compared to the calculated AUC values for free drug in plasma of 0.19 and 0.42 mumol.h/liter, respectively.","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),[h·μM] / [l],0.19,166924,DB00276,Amsacrine
,2297692,AUC,"Tumor AUC values for CI-921 and amsacrine were 68 and 37 mumol.h/liter, respectively, as compared to the calculated AUC values for free drug in plasma of 0.19 and 0.42 mumol.h/liter, respectively.","Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297692/),[h·μM] / [l],0.42,166925,DB00276,Amsacrine
,1914082,Ki,"mAMSA appeared to inhibit MTX hydroxylation competitively, exhibiting a Ki of 3 microM.",Inhibition of 7-hydroxymethotrexate formation by amsacrine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1914082/),μM,3,176896,DB00276,Amsacrine
,3409236,AUC,"In (a) while the mean AUC for MTX (15815 +/- 1317 microMmin) with mAMSA (+mAMSA) remained essentially unchanged relative to that without mAMSA (-mAMSA) at the same dose (14832 +/- 5151 microMmin), the mean AUC of the metabolite 7-hydroxymethotrexate (7-OH MTX) decreased from 9338 +/- 3057 (n = 6, -mAMSA) to 5794 +/- 1371 microMmin (n = 6, +mAMSA).",Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409236/),μMmin,15815,201798,DB00276,Amsacrine
,3409236,AUC,"In (a) while the mean AUC for MTX (15815 +/- 1317 microMmin) with mAMSA (+mAMSA) remained essentially unchanged relative to that without mAMSA (-mAMSA) at the same dose (14832 +/- 5151 microMmin), the mean AUC of the metabolite 7-hydroxymethotrexate (7-OH MTX) decreased from 9338 +/- 3057 (n = 6, -mAMSA) to 5794 +/- 1371 microMmin (n = 6, +mAMSA).",Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409236/),μMmin,14832,201799,DB00276,Amsacrine
,3409236,AUC,"In (a) while the mean AUC for MTX (15815 +/- 1317 microMmin) with mAMSA (+mAMSA) remained essentially unchanged relative to that without mAMSA (-mAMSA) at the same dose (14832 +/- 5151 microMmin), the mean AUC of the metabolite 7-hydroxymethotrexate (7-OH MTX) decreased from 9338 +/- 3057 (n = 6, -mAMSA) to 5794 +/- 1371 microMmin (n = 6, +mAMSA).",Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409236/),μMmin,9338,201800,DB00276,Amsacrine
,3409236,AUC,"In (a) while the mean AUC for MTX (15815 +/- 1317 microMmin) with mAMSA (+mAMSA) remained essentially unchanged relative to that without mAMSA (-mAMSA) at the same dose (14832 +/- 5151 microMmin), the mean AUC of the metabolite 7-hydroxymethotrexate (7-OH MTX) decreased from 9338 +/- 3057 (n = 6, -mAMSA) to 5794 +/- 1371 microMmin (n = 6, +mAMSA).",Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409236/),μMmin,5794,201801,DB00276,Amsacrine
,3409236,fractional rate conversion,The fractional rate conversion of MTX to this metabolite (fmi) also decreased from 0.60 +/- 0.19 (n = 6) to 0.40 +/- 0.10 (n = 6) (P less than 0.05).,Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409236/),,0.60,201802,DB00276,Amsacrine
,3409236,fractional rate conversion,The fractional rate conversion of MTX to this metabolite (fmi) also decreased from 0.60 +/- 0.19 (n = 6) to 0.40 +/- 0.10 (n = 6) (P less than 0.05).,Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409236/),,0.40,201803,DB00276,Amsacrine
,17981420,flow rate,"Chromatographic separation was achieved on a reversed phase C 18 column (250 mm x 4.6mm, particle size 5 microm, Gemini) using isocratic elution (acetonitrile and 0.01 M sodium acetate buffer pH 4.0, 45/55, v/v) at a flow rate of 1 ml/min.",Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981420/),[ml] / [min],1,238244,DB00276,Amsacrine
,17981420,total chromatographic run-time,"The total chromatographic run-time was 8 min with asulacrine and internal standard eluting at approximately 4.7 and approximately 6.5 min, respectively.",Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981420/),min,8,238245,DB00276,Amsacrine
,17981420,total chromatographic run-time,"The total chromatographic run-time was 8 min with asulacrine and internal standard eluting at approximately 4.7 and approximately 6.5 min, respectively.",Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981420/),min,4.7,238246,DB00276,Amsacrine
,17981420,total chromatographic run-time,"The total chromatographic run-time was 8 min with asulacrine and internal standard eluting at approximately 4.7 and approximately 6.5 min, respectively.",Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981420/),min,6.5,238247,DB00276,Amsacrine
,17981420,Limit of quantification,Limit of quantification was 0.1microg/ml.,Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981420/),[μg] / [ml],0.1,238248,DB00276,Amsacrine
,17981420,recoveries,Mean recoveries from plasma were 100-105%.,Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981420/),%,100-105,238249,DB00276,Amsacrine
,27019595,polydispersity index,"The results showed that amsacrine analog-loaded SLN was 36.7 nm in particle size, 0.37 in polydispersity index, and 34.5±0.047 mV in zeta potential.",Amsacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27019595/),,0.37,239577,DB00276,Amsacrine
,27019595,zeta potential,"The results showed that amsacrine analog-loaded SLN was 36.7 nm in particle size, 0.37 in polydispersity index, and 34.5±0.047 mV in zeta potential.",Amsacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27019595/),m,34.5,239578,DB00276,Amsacrine
,11488768,Ki,"Vinblastine, vincristine and amsacrine at 500 microM significantly (P < 0.05) inhibited DMXAA glucuronidation (Ki = 319, 350 and 230 microM, respectively), but not 6-methylhydroxylation in human liver microsomes.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,319,255424,DB00276,Amsacrine
,11488768,Ki,"Vinblastine, vincristine and amsacrine at 500 microM significantly (P < 0.05) inhibited DMXAA glucuronidation (Ki = 319, 350 and 230 microM, respectively), but not 6-methylhydroxylation in human liver microsomes.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,350,255425,DB00276,Amsacrine
,11488768,Ki,"Vinblastine, vincristine and amsacrine at 500 microM significantly (P < 0.05) inhibited DMXAA glucuronidation (Ki = 319, 350 and 230 microM, respectively), but not 6-methylhydroxylation in human liver microsomes.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,230,255426,DB00276,Amsacrine
,11488768,Ki,"Daunorubicin and N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide (DACA) at 100 and 500 microM showed significant (P < 0.05) inhibition of DMXAA 6-methylhydroxylation (Ki = 131 and 0.59 microM, respectively), but not glucuronidation.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,131,255427,DB00276,Amsacrine
,11488768,Ki,"Daunorubicin and N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide (DACA) at 100 and 500 microM showed significant (P < 0.05) inhibition of DMXAA 6-methylhydroxylation (Ki = 131 and 0.59 microM, respectively), but not glucuronidation.","Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488768/),μM,0.59,255428,DB00276,Amsacrine
above,1999001,steady-state plasma concentrations,"Severe mucositis (Pediatric Oncology Group grades 3-4) occurred in 18% of cases, all of whom showed teniposide steady-state plasma concentrations above the median population value (11.9 micrograms/ml; P less than 0.0001).",Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1999001/),[μg] / [ml],11.9,270457,DB00276,Amsacrine
